Kristina Shurtleff, MD
Family Medicine · Henderson, NVNPI 1811916216
Payments from drug & device makers
Across 241 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$319
- Amgen$307
- Novo Nordisk$276
- Merck$247
- Boehringer Ingelheim$235
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,27196%
- Education$1854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 64 | $1,001 |
| GSK | 16 | $319 |
| Amgen | 14 | $307 |
| Novo Nordisk | 19 | $276 |
| Merck | 11 | $247 |
| Boehringer Ingelheim | 11 | $235 |
| Johnson & Johnson(2 entities) | 4 | $189 |
| Esperion Therapeutics, Inc. | 4 | $173 |
| AstraZeneca | 8 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $146 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $136 |
| Mannkind Corporation | 9 | $129 |
| Pfizer | 7 | $128 |
| Astellas Pharma US Inc | 6 | $108 |
| Baxter Healthcare | 2 | $102 |
| Novartis | 5 | $91 |
| Advanced Respiratory, Inc | 5 | $81 |
| Kowa Pharmaceuticals America, Inc. | 4 | $75 |
| Dexcom, Inc. | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Mylan Specialty L.p. | 3 | $59 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $46 |
| Amarin Pharma, Inc. | 2 | $37 |
| Exact Sciences | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Nalpropion Pharmaceuticals LLC | 2 | $26 |
| Lilly USA, LLC | 2 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
| Inogen, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,456 in reported general payments places this provider in the 85th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 188 | $232,337 |
| MounjaroTirzepatide | 143 | $176,002 |
| EntrestoSacubitril/Valsartan | 77 | $93,220 |
| EliquisApixaban | 78 | $91,816 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $86,581 |
| CreonLipase/Protease/Amylase | 51 | $84,013 |
| FarxigaDapagliflozin Propanediol | 73 | $72,862 |
| XifaxanRifaximin | 25 | $67,797 |
| LinzessLinaclotide | 52 | $55,884 |
| NucalaMepolizumab | 11 | $40,577 |
| TradjentaLinagliptin | 37 | $33,355 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $30,284 |
| Repatha SureclickEvolocumab | 24 | $30,246 |
| TrulicityDulaglutide | 23 | $25,053 |
| WegovySemaglutide | 12 | $21,535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy, Rybelsus | $276 | $272,442213 claims |
| Lilly USA, LLCMounjaro, Trulicity | $25 | $201,056166 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $319 | $149,908148 claims |
| AbbVieCreon, Linzess | $1,001 | $139,898103 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $155 | $119,157154 claims |
| NovartisEntresto | $91 | $93,22077 claims |
| PfizerEliquis | $128 | $91,81678 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor | $136 | $88,21841 claims |
| Boehringer IngelheimTradjenta, Jardiance | $235 | $53,79751 claims |
| Johnson & JohnsonInvega Sustenna | $189 | $20,14213 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $58 | $15,40318 claims |
| Astellas Pharma US IncMyrbetriq | $108 | $9,26314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 902 family medicine providers in Nevada.
Other family medicine in Henderson
- Rita ChuangHenderson$476K
- Vincent MirkilHenderson$82K
- Ibrahim FakhouriHenderson$51K
- Badi EghterafiHenderson$38K
- Gautham ReddyHenderson$17K
- Yuan-Chung ChenHenderson$13K
- Travis HailstoneHenderson$8K
- Rogelio MachucaLas Vegas$3.3M
- Maxine InghamLas Vegas$2.9M
- Elliot ShinLas Vegas$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.